ChemicalBook > CAS DataBase List > Docaravimab
Docaravimab
- Product Name
- Docaravimab
- CAS No.
- 2247196-23-0
- Chemical Name
- Docaravimab
- Synonyms
- Docaravimab;Research Grade Docaravimab;Research Grade Docaravimab (DVV03501)
- CBNumber
- CB310616975
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Docaravimab Chemical Properties,Usage,Production
Uses
Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies[1].
References
[1] Wilkinson I, et, al. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022 Jan-Dec;14(1):2123299. DOI:10.1080/19420862.2022.2123299
Docaravimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Docaravimab Suppliers
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
2247196-23-0, DocaravimabRelated Search:
Coltuximab Ravtansine
Ivonescimab
Rivabazumab
Research Grade Acazicolcept (DHC83404)
dinutuximab
Immunoglobulin G1, anti-(human interferon g) (human-mouse monoclonal HuZAF g1-chain), disulfide with human-mouse monoclonal HuZAF light chain, dimer
Rocatinlimab
Opucolimab
Tilogotamab
Miromavimab